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Background: Risk assessment of chemicals and other agents must be accurate to protect health. We analyse
the determinants of a sensitive chronic toxicity study, risk assessment's most important test. Manufacturers
originally generate data on the properties of a molecule, and if government approval is needed to market it,
laws globally require toxicity data to be generated using Test Guidelines (TG), i.e. test methods of the
Organisation for Economic Cooperation and Development (OECD), or their equivalent. TGs have advantages,
but they test close-to-poisonous doses for chronic exposures and have other insensitivities, such as not
testing disease latency. This and the fact that academic investigators will not be constrained by such
artiﬁcial methods, created a de facto total ban of academia's diverse and sensitive toxicity tests from most
risk assessment.
Objective: To start and sustain a dialogue between regulatory agencies and academic scientists
(secondarily, industry and NGOs) whose goals would be to (1) agree on the determinants of accurate
toxicity tests and (2) implement them (via the OECD).
Discussion: We analyse the quality of the data produced by these incompatible paradigms: regulatory
and academic toxicology; analyse the criteria used to designate data quality in risk assessment; and
discuss accurate chronic toxicity test methods.
Conclusion: There are abundant modern experimental methods (and rigorous epidemiology), and an
existing systematic review system, to at long last allow academia's toxicity studies to be used in most risk
assessments.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
1. Introduction
Our objective in this article is to start an intensive dialogue
between academic researchers and risk assessment agencies, on
what are the determinants of reliable chronic toxicity test for a risk
assessment of chemicals (‘risk assessment’). Two opposing para-
digms control toxicology – ‘academic’ and ‘regulatory’. We deﬁne
the former as investigations by researchers largely at universities
and medical institutions. The latter however developed mostly in
the nascent organic chemistry industry (especially synthetic phar-
maceuticals), creating the toxicity test methods (Borzelleca, 1994)
on which risk assessment relies on today, as we will demonstrate. We
concentrate on the chronic exposure test, as it largely determines the
regulation of agents in commerce, representing population-wide
exposures. Risk assessment's methods were uniﬁed in a globally-
adopted four-step paradigm by the US National Research Council's
‘Red Book’ (USNRC, 1983).
Other than an occasional regulator's generation of exposure
data, a large information asymmetry exists in risk assessment.
Companies investigate the physio-chemical character of molecules
for marketable properties, including interactions with biologic
systems. If a molecule appears worth commercialising, these data
inform the necessary toxicity investigations (including on the
agent's behaviour in organisms – adsorption to excretion), such
as the dose level for in vitro and then in vivo acute toxicity tests.
Such test results inform the dose levels for a sub-chronic exposure
test, whose potency results ﬁnally informs the doses for the
chronic toxicity test (Klaassen et al., 2013). This ‘dose ranging’
process is needed for a risk assessment, which aims to ﬁnd a safe
dose under all anticipated exposure scenarios.
The manufacturer performs these dose-ranging toxicity tests
because the molecule promises proﬁt if found safe enough to use.
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This basic conﬂict of knowledge and proﬁt can cause a selective
presentation of toxicity data when the agent undergoes approval
for marketing (pre-market risk assessment). Indeed, many dozens
of reviews show that ﬁndings of drug efﬁcacy and risk are
favourable to the manufacturer's interests (e.g. Sterne et al.
(2008)), while publically funded tests return realistically mixed
outcomes. Eight known such reviews exist for industrial chemicals
(listed, Section 2.3), and all ﬁnd the same correlation as the
pharmaceutical reviews do.
1.1. How standardized toxicity test methods came to be dominate
risk assessment
A key event in risk assessment occurred in the 1970s when a
third of all the USA's regulatory chemical and pharmaceutical
toxicity tests were suddenly brought into question by a whistle-
blower who revealed massive fraud at just one laboratory used
exclusively by industry, Industrial Bio-Test (Schneider, 1983). In
response, the US Food and Drug Administration (US FDA) in 1978–
1979 established mandatory Good Laboratory Practice (GLP)
requirements for non-human tests (USFDA, 2014). GLP requires
transparent, detailed documentation of the laboratory work and
explicitly assigns responsibility for the various steps in an experi-
ment, thereby increasing accountability; discouraging dishonest or
criminal behaviour and enhancing the replicability (precision)
of data.
US FDA's GLP was immediately adopted by the US Environ-
mental Protection Agency (US EPA), then rapidly by regulatory
agencies worldwide. The Organization for Economic and Commer-
cial Development (OECD) member countries began adhering to
GLP standards in their 1981 Mutual Acceptance of Data (MAD)
decision (OECD, 2014a).
Crucially, MAD also marked the appearance of the OECD's Test
Guidelines (TG) – standardized detailed protocols (methods) for
performing toxicity tests. MAD requires that only TG and GLP-
compliant toxicity tests be used in a risk assessment by any OECD
member country. This strong OECD initiative – several detailed
toxicity test methods begun and promulgated in just three years
from the appearance of GLP – may indicate risk assessors' new
determination to ensure reliable and standardized data. Equally, it
may indicate industry's desire to retain control of the crucial data
going into risk assessment. We speculate that after industry was
forced to comply with GLP, it lobbied the OECD to use their
existing (Borzelleca, 1994) insensitive toxicity test methods as
mandatory TGs; in effect creating a global shield against use of
academia's ﬁndings to determine risk.
We label the OECD's test methods ‘TG-GLP’, GLP being essen-
tially a generic TG. Today, government bodies in developed
countries oversee the creation/revision of toxicity test methods,
all coordinated with the OECD's Working Group of the National
Coordinators of the Test Guidelines Programme (WNT). The WNT
is composed of the lead chemical agency of those countries (OECD,
2014b). The WNT accepts nominations for a new or revised toxicity
test method from these national agencies, ﬁnalises it as a TG, then
OECD promulgates it to member countries and lately especially to
the rest of world (OECD, 2010). A few countries (such as the USA)
create their own toxicity test methods, but these are entirely
coordinated with TGs (USEPA, 2010).
Thus MAD drives statutorily-required use of TG-GLP in pre-
market risk assessments across the world (OECD, 2014b; USEPA,
2014a); and, because many agents need a risk assessment in
various jurisdictions over the decades, the majority of all risk
assessments are ‘pre-marketing’, and so must use TG-GLP methods
(parenthetically, many chemical uses require no approval to be
used in commercial products, e.g. household cleaning or personal
care products). We will show how the TG-GLP test methods,
though with beneﬁts, fail to detect much toxicity.
2. Discussion
2.1. How TG-GLP bars academia's studies from almost all risk
assessment
Use of TG-GLP would provide academic investigators with
adequate study power and some assurance of data quality. But
science already has good data quality protocols, such as conﬁdence
intervals and peer review. The rather insensitive and artiﬁcial TG
protocols hinder discovery. Thus the net effect of requiring TG-GLP in
risk assessments is to entirely exclude academia's results from most
assessments.
Regulatory agencies issue guidance on performing risk assess-
ment, for use by their staff and industry (OECD, 2012a; USEPA,
1999; EFSA, 2010; EChA, 2011). These reinforce the laws to use TG-
GLP by advising that TG-GLP studies deliver the most reliable data
for evaluating toxicity. A crucial underpinning to this conclusion is
a published guide to data reliability authored by employees of the
chemical multinational BASF (Klimisch et al., 1997). The guidances
all say (e.g. EChA, (2010)) that ‘Klimisch’ should be used to ﬁnd the
most reliable studies. But Klimisch simply states that TG-GLP
studies return the most reliable data, giving them its top rank of
‘1’ (it ranks other qualities, but ‘reliability’ is its key criterion).
The European Union (EU)'s Health Commissioner has testiﬁed:
‘While it is correct that GLP does not evaluate the scientiﬁc quality
and reliability of a study, it is the only internationally recognised
quality system that monitors the organisational process and the
conditions under which health and environmental safety studies
are planned, performed, monitored, recorded, archived and
reported.’ (Dalli, 2011). Initial reviews suggest that adherence to
TG-GLP criterion may not produce consistent results compared to
other data quality criteria (Ågerstrand et al., 2014). Despite these
concerns, the Klimisch criterion on the reliability of data is now an
almost universally utilised (Ågerstrand et al., 2014) justiﬁcation
that TG-GLP methods produce the most reliable data.
Industry and regulators often say that academia's lack of dose
ranging and heterogeneous methods make it impossible to eval-
uate the quality of their data; so academia's studies are only
‘useful for generating hypotheses’ (EFSA, 2012a, 2012b). They say
that there is no barrier to use of academic studies, so long as they
were of equivalent quality to TG-GLP studies...yet their criterion for
study quality is TG-GLP (EFSA, 2012a; USNTP, 2013b).
Thus tens of thousands of published toxicity ﬁndings from
academia are being ignored. At a conference of 300 senior risk
assessors, not one when asked in plenary could spontaneously
name a single pre-market risk assessment that did not rely on TG-
GLP tests from industry to calculate its chronic safe dose (Twee-
dale, A.C., personal communication). Among the tens of thousands
of pre-market risk assessments performed globally over several
decades, we know of only one recent one (for vinyl cyclohexane,
by the French agency ANSES – we would be interested to hear of
any others).
Our intent is to break this circular logic, and get risk assessors
to evaluate the reliability of academia's studies, not to simply
exclude them.
The other type of chemical risk assessment is the post-
marketing or ‘review’ risk assessment – often performed after
the accuracy of a safe dose has been questioned. These are not
required to, but often do, use a TG-GLP study as their key study.
Nevertheless the accumulation of academia's published toxicity
studies haltingly become relied on in post-market risk assess-
ments. For example the US EPA's Integrated Risk Information
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System (IRIS) (USEPA, 2014b) uses low-dose toxicity ﬁndings from
academia to declare a safe chronic exposure dose for some
chemicals. Industry greatly disputes the accuracy of IRIS's calcu-
lated safe doses (Rosenberg, 2011), so TG-GLP based LOAELs are
only slowly replaced – e.g. the IRIS safe dose of bisPhenol-A (bPA)
has not yet changed despite hundreds of published low dose
toxicity ﬁndings. The US National Research Council thoroughly
evaluated these controversies and concluded IRIS is very useful
and becoming more so (with recommendations); while contra-
dicting industry's chief claims (USNRC, 2014a).
2.2. The key sensitivity difference between academic and TG-GLP
methods
TG-GLP methods have strengths. They make the parties of an
experiment accountable for all decisions and test results, increas-
ing data reliability. They are standardized and transparent,
enabling inter-study comparison, and so are also easier to replicate
(precision) than academia's studies. They use sufﬁcient animal
numbers to potentially detect weak effects, and they system-
atically test doses from poisonous to the end of poisoning. They
are more speciﬁc (few false positives) than academia's tests.
But more speciﬁcity often means less sensitivity, a key criterion
if health is to be protected. By using quasi-poisonous doses and
other insensitivities (Section 2.4), the effects and toxicity thresh-
olds elicited by chronic TG methods can be rather insensitive –
liable to false negatives. Despite testing chronic exposure periods,
the TGs detect largely the end of poisoning, as follows (Klaassen et
al., 2013).
Chronic TGs aim to discover both a ‘lowest observable adverse
effect level’ (LOAEL, the lowest dose an adverse effect is observed
at), and a ‘no observable adverse effect level’ (NOAEL, the highest
dose at which no adverse effect is observed); to set the safe daily
dose for almost a lifetime of exposure. A ‘Maximum Tolerated
Dose’ (MTD) is found by lowering the dose from acutely poisonous
levels. That is, the chronic dose must be high enough to observe
signiﬁcant toxic effects from the limited number of animals that
can be afforded by these expensive long term tests; but low
enough to prevent most animals from wasting away from poison-
ing. Thus the doses of a TG-GLP chronic test typically range from
the MTD (or just below it) for the highest dose, to 100-fold or so
below the MTD for the lowest dose. In effect they are quasi-
poisonous doses over most of a mammal's life.
Indeed, our readings of risk assessments show that the high
doses of chronic TG elicit a slow poisoning: typically weight loss
and gross histopathologic change of organs; usually the kidneys
and liver, which try to excrete poisonous molecules. Poisoning by
deﬁnition occurs in a linear dose–response fashion, so these high
TG doses crucially tend to produce a LOAEL and a NOAEL, allowing
a safe dose to be calculated and the risk assessment to proceed (if no
LOAEL is found, the doses may be lowered and the test repeated).
2.3. But are these actual L/NOAELs?
No one disputes that ﬁnding a monotonic dose–response (D/R)
relationship – no reversal of the dose–response (D/R) slope –
supports causation, and they are also a common ﬁnding in
academia's studies. But monotonicity is not the only display of
toxicity and there are at least seven biologic reasons why a lower
dose can be more potent than a higher one, indeed perhaps 20% of
the time, ﬁnding over 800 examples (Vandenberg, 2014). Bio-
chemistry – life – is resilient, but complex, and it often occurs at
very low signal strengths (Ray and Gough, 2002); so life can be
vulnerable to agents it did not evolve with.
But use of realistic doses are not even contemplated by the TGs;
e.g. EU risk assessors recently dismissed non-monotonic terato-
genic effects of the herbicide glyphosate, though they were found
in tests designed and performed for risk assessment (Antoniou
et al., 2012).
The insensitivity of the TG methods was directly demonstrated
in a side-by-side comparison of test methods employed to inves-
tigate mammary gland toxicity (Makris, 2011), plus a companion
paper of expert group analysis of the mammary gland microscope
slides of the compared studies (Rudel et al., 2011); together they
demonstrate that TG methods failed to detect various important
signs of toxicity to this mammalian organ.
Support for low dose toxicity also comes from epidemiology's
large, fast-growing literature, which correlates humanity's low-
dose exposures with diseases, avoiding extrapolation across spe-
cies. Epidemiologic methods are conservatively biased to the null
hypothesis (Nachman et al., 2011): increasingly they are long-
itudinal (allowing cause to precede effect), use large sample sizes,
have accurate exposure data, and control confounders better
(Nachman et al., 2011). In sum, epidemiology increasingly con-
tributes to establishing causation. The US EPA's ‘Dioxin Reassess-
ment’ (USEPA 2010), the most extensive risk assessment ever – on-
going for more than 25 years – relies on epidemiology to ﬁnd (as
draft) that very low dioxin doses are dangerous.
Finally, the insensitivity of the TG test methods is evidenced by
at least eight published reviews comparing industry's toxicity
Table 1
In-vivo refutations of risk assessment chronic toxicity L/NOAELs.
Chemical L/NOAEL in a risk assessment Potency in published literature
Glyphosate, herbicide 100 mg/kg d- (circa NOAEL of industry's key studies) 4.87 mg/kg d-, no NOAEL, tests glyphosate (Benedetti et al., 2004).
HexaBromo CycloDodecane
(HBCDD) Flame Retardant
100 ppm (8.1–21.3 mg/kg d-) NOAEL REACh Authorisation
(Saegusa et al., 2009).
0.9 mg/kg d- single oral dose altered mouse spontaneous behaviour,
no NOAEL Eriksson et al., 2006).
Tri-n-Butyl Tin Molluscide,
fungicide.
25 μg/kg d- NOAEL (Vos et al., 1990). 0.5 μg/kg d- (5.42 nM in water, circa human body burdens):
increased obesity parameters, through F3 unexposed generation
(Chamorro-García et al., 2013).
2,4-D, herbicide 62.5 mg/kg d- LOAEL (Charles et al., 1996). 2.5 mg/kg d- (in food; also as single i.p. dose): hormone alteration,
lactation problems (Stürtz et al., 2010).
Cadmium 10 μg/kg d- via food NOAEL (USEPA 2014c). 5 μg/kg (27 nM/kg) single i.p. inj. proliferated F reproductive
organs in maturity, no NOAEL (Johnson et al., 2003).
Arsenic 170 μg/L (drinking water) LOAEL (USEPA 2014d) 10 μg/L (10 ppb, EPA alleged safe level) in ad libid. water: decreased
growth in utero and F1, no NOAEL (Kozul-Horvath et al., 2012).
Formaldehyde 82 mg/kg/d-oral LOAEL/15 mg kg d- NOAEL: decreased rat
organ/body weights, (USEPA, 2014e; EChA, 2014); 3.2 mg/m³
chronic inhalation NOEC (EChA, 2014); 0.1 mg/m³ chronic local
eff. NOEC (EChA, 2014).
1 mg/kg d- (10 mg formaldehyde/L water ad libid. S-D rats):
cancers, no NOAEL (Soffritti et al., 2002). 0.1 mg/m³: asthma
(human), no NOAEL (Casset et al., 2006); 0.52 mg/m³ asthma, no
NOAEL (Qiao et al., 2009).
Not just endocrine disruptors cause low-dose toxicities.
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studies with academia's studies (Bekelman et al., 2003; Diels et al.,
2011; Domingo and Bordonaba, 2011; Fagin and Lavelle, 2002;
Hayes, 2004; Lesser et al., 2007; Swaen and Meijers, 1988; vom
Saal and Hughes, 2005). These clearly show that industry studies
ﬁnd little or no toxicity, while publicly funded studies of the same
chemical realistically yield mixed results, including many ﬁndings
of low dose toxicity.
Agents including arsenic, lead, mercury, ozone, particulate
matter and dioxin-like compounds have had their ‘safe’ dose
repeatedly lowered over the decades until it is generally conceded
that they may have no safe exposure level, but this has not
occurred for any strictly commercial agents. Rather, regulatory
agencies while respecting the ﬁndings of academic science as
‘hypothesis-raising’, seem to require the more unrealistic standar-
dized data resulting from dose-ranging.
Yet one may pick any well-known agent (so it has a large
enough published toxicity literature) and see published ﬁndings of
chronic mammalian toxicity at doses lower than the LOAEL
claimed in its risk assessments. We list a few dozen examples in
Tables 1 and 2 (some are even more potent than some of the
LOAELs in the IRIS database). Parenthetic to our purpose, we note
that ecological risk assessment seldom performs any chronic
exposure test at all. However ﬁxing the mammalian chronic
assay's insensitivity would beneﬁt all species.
2.4. What makes TG-GLP tests so insensitive?
Any study has shortcomings, but why do TG-GLP methods so
regularly fail to ﬁnd toxicity at the levels that organisms are
typically exposed to, when other test methods do? Here are the
main insensitivities of TG chronic test methods:
(1) A TG test sacriﬁces the animals at the end of dosing, at human
equivalent of circa 60 years old, before most chronic disease
manifests – e.g. 77% of malignant tumours are diagnosed after
age 55 in the USA (ACS, 2013).
(2) Not enough tests of developmental toxicity are done, despite
the complex vulnerability of development, which drives much
disease, even in adulthood (Hanson and Gluckman, 2011).
(3) Data from concurrent negative controls in a TG-GLP experi-
ment are allowed (OECD, 2012b) to be diluted, even over-
ridden, by historical control data drawn from experiments
carried out in a wide range of different conditions (accord-
ingly, they are used in many risk assessments). Some of the
variables not well controlled when using the often secret
historical controls include strain and origin of animals, labora-
tory in which the experiment was carried out, dietary factors;
environmental contaminants in air, bedding, food, and water;
differences in diagnostic criteria among pathologists, and the
year in which the experiment was performed; all which can
produce very different results (Haseman, 1984; Hardisty,
1985).
(4) Positive controls (when feasible) limit false negative results
(Myers et al., 2009), but are never mentioned in the TGs or in
guidance.
(5) Toxicity is almost always detected with the light microscope
and a few gross biochemistry measures, rather than also
employing academia's advanced imaging and biochemistry
methods (Koshland Jr., 1998).
(6) As just described, the TG's high dose levels tend to elicit a
quasi-poisoning syndrome that is irrelevant to the effect of the
doses encountered in the biosphere, which remain untested
by TGs.
Table 2
In-vivo refutations of most protective TTC's assumed NOAEL, 150 μg/kg bw d-.
Chemical N/LOAEL (μg/kg bw d-) TimesoTTC NOAEL ( ) Reference
Diethylstilbesterol (DES) 0.018 8333 Bøgh et al. (2001)
Bisphenol-A 0.025 6000 Muñoz-de-Toro et al. (2005)
HCBþ1,2,3-TCBenzene 0.1 1500 Valkusz et al. (2011)
BDE-47 0.2 750 Abdelouahab et al. (2009)
Ethinylestradiol (EE2) 0.2 750 Vosges et al. (2008)
TriButylTin 0.4 375 Meador et al. (2011)
Dicamba 0.9 167 Cavieres et al. (2002)
Atrazine 1 150 Belloni et al. (2007)
Bisphenol-A 2 150 Melnick et al. (2002)
Fenarimol (pyrimidine fungicide) 2 75 Park et al. (2011)
BDE-47 (Br diphenyl ether) 2 75 Suvorov and Takser (2011)
Deltamethrin 3 50 Issam et al. (2009)
Dieldrin 5 30 Walker et al. (1969)
Haloxyfop methyl 5 30 USEPA (2014f)
Triﬂumazole 8.6 17 Li et al. (2012)
Di-n-butyl phthalate 10 15 Hoshi and Ohtsuka (2009)
Perchlorate 10 15 Yu et al. (2002)
PFOA 10 15 Macon et al. (2011)
Octylphenol 10 15 Alworth et al. (2002)
Methoxychlor 10 15 Bøgh et al. (2001)
DEHP (phthalate) 15 10 Andrade et al. (2006)
o,p0-DDT 18 8 Palanza et al. (1999)
Methoxychlor (two at same dose) 20 8 Gioiosa et al., (2007), Armenti et al. (2008)
Toxaphene 50 3 Olson et al. (1980)
BDE-99 60 212 Kuriyama et al. (2007)
Nonylphenol 100 112 Yu et al. (2011)
For many years industry has promoted the Threshold of Toxicologic Concern (TTC) as a substitute for chronic toxicity testing. A TTC is a claimed safe dose for effect categories
of agents (genotoxic, endocrine-disrupting, etc. (the latter's appropriateness for the TTC is still being debated). A TTC is set below the LOAELs of up to a few hundred existing
toxicity results; but with the usual preference for TG-GLP-generated results. Consequently, it is just as easy to ﬁnd examples of more potent toxicity than a TTC as it is for
those in Table 1. Here even the most protective of the TTCs, for Cramer Class III agents: 1.5 μg/kg d- is shown to not be protective. Many of our examples dose by feed/gavage, so
the elicited toxicity is after ﬁrst pass metabolism and excretion. Our example doses are mostly LOAELs while the TTC uses mostly NOAELs, so our refutations are stronger yet.
We include examples of natural hormones to emphasise how potent hormones can be. Finally we assume the standard 100-fold uncertainty factors went into this TTC, for a
putative ‘universal’ NOAEL of 150 μg/kg d-.
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In contrast, academic researchers develop whatever methods
sufﬁce to investigate an agent's chronic toxicity; and they use the
time-tested quality control methods of peer review and publishing
(albeit these are undergoing challenge). The later allows further
peer critique. Also, a study's methods and raw data are available
for inspection after publication, according to science customs.
The US National Toxicology Program's publically funded chronic
toxicity tests also – as TG-GLP methods do – use doses high enough
to reliably detect effects for a set number of test animals. None-
theless their results have been tested and found to predict carcino-
genicity (Huff, 2002; Maronpot et al., 2004), and continually
improve the sensitivity of their methods. The Ramazzini Institute
near Bologna, Italy employs an opposite approach, using as many
animals as are needed to reliably detect low dose chronic effects.
Their tests regularly ﬁnd toxicity at doses deemed safe under TG-
GLP methods (Chiozzotto et al., 2012; Soffritti et al., 2008) and their
data were recently partially validated and recommended for use in
risk assessment (Box 1). Note that in the USA and likely elsewhere,
animal welfare concern prevents federally-funded life science aca-
demics from using larger animal groups than needed to detect a
signiﬁcant effect (vom Saal and Hunt, 2012); thus TG-GLP propo-
nents can misleadingly claim that academia's studies are too
underpowered compared to theirs; as the USFDA did in a 2012
post-market assessment of bPA risks. Yet proper controls and other
method issues have a greater inﬂuence than group size does on
sensitivity (A. Soto, personal communication).
Regulators correctly note (USNTP, 2013a) the increasing use of the
Benchmark Dose (BMD) to establish a risk assessment's safe doses.
Rather than searching for a LOAEL which assumes no toxicity is
possible below it, a BMD is the dose at which toxicity ﬁrst manifests.
This encourages testing of low doses (though distinguishing harmful
from harmless changes may be controversial). A validation of BMDs
using 352 long studied chemicals not only veriﬁed that more testing
at low doses improved the accuracy of a dose/response data set, but
that these lower doses frequently caused toxicity below the alleged
NOAELs (Wignall et al., 2014). Allowing academia's low dose toxicity
tests to be considered in risk assessment would encourage wider
adoption of BMD in risk assessment.
2.5. Persuading risk assessors to consider academia's toxicity data
To recapitulate, academia's toxicity studies are excluded from
most risk assessments, which instead use data from the somewhat
artiﬁcial and insensitive TG-GLP tests. Rapidly gaining reliability
and realism are in vitro and in silico test methods (Birnbaum,
2013), as well as substitutions of models for toxicity testing, e.g.
the Threshold of Toxicologic Concern (TTC – see Table 2 for
description), which regularly are proposed to improve risk assess-
ment. However, the chronic mammalian bioassay should be the
main focus of improving accuracy – as it most realistically models
human risks.
Given the demonstrated insensitivities of the TG-GLP methods,
there is an urgent need for national chemical safety regulators to
dialogue with academic researchers, to intensively debate the
determinants of accurate (both sensitive and speciﬁc) and precise
(replicable) chronic toxicity test methods – i.e., of reliable data. The
following modiﬁcations to pre-market risk assessment are indi-
cated. They are long-term goals, as achieving them will require
much dialogue.
2.5.1. For agents not previously assessed: independent testing
As described, the inventor initially has all knowledge on their
agent. Their role in the future should be only to provide the agent
and their data on it (with conﬁdentiality of competition-sensitive
business information); and to pay the cost of independent testing
(only through fees paid to national treasuries, in order to dilute
their inﬂuence). Financially independent academia should be
statutorily declared to be the rebutably-preferred source of data
Box 1–Further ways to improve risk assessment.
Adopt methods and the offer of learned academic societies
An offer of learned societies of the life sciences (ASHG, 2011)
to lend their unmatched expertise in investigating toxicity
must be seriously considered by regulators. Such a sensitive
chronic toxicity protocol is already in use at laboratories such
as Italy’s Ramazzini Institute (at least one academic lab in the
USA, perhaps elsewhere, are doing the same). Despite the
expense, the Ramazzini laboratory estimate human exposure
levels to determine the dose and thus the necessary animal
groups’ size. They expose animals in utero and through
development and allow test animals to live out their lives – at
least 120–130 weeks of age for rodents – as chronic diseases
take time to develop (Chiozzotto et al., 2012). Their ‘GLP Life
Test’ laboratory is GLP-certified, a key demand of risk
assessors. While regulators have cited false positive cancer
slide readings (infections, not cancer) by Ramazzini Institute,
a new leading experts examination of their microscope slides
prove that any confounding by infections is limited to three
cancer types. Otherwise, their conclusion is that Ramazzini’s
sensitive test methods are especially useful for risk assessors
(Gift et al., 2013) – which USEPA and the EU’s EFSA had
previously rejected.
Adopt NIEHS’s TiPED
Recent federal USA initiatives on risk assessment (Birnbaum
et al., 2013) include a Tiered Protocol for Endocrine Disrup-
tion (TiPED) framework by the US National Institute of
Environmental Health Sciences (NIEHS) for testing the effects
of low doses (Schug et al., 2013). TiPED is an ideal risk
assessment framework for all endpoints, not just endocrine
effects. TiPED would integrate all available data on an agent,
from modelling through to chronic mammalian exposures,
with all methods to be kept at the ‘cutting-edge’ by the best
scientists in these various fields.
Rescue NRC’s Silver Book recommendations
We strongly support the ‘Silver Book’ recommendations of
the US National Research Council on re-inventing risk
assessment (USNAS, 2009), which inter alia would expand
use of low dose test methods by abandoning the assumption
of a threshold (safe) dose (only carcinogenicity tests currently
do). But the implementation of these recommendations
seems to have been entrusted to the very parties – industry
and regulators – who believe today’s insensitive TG-GLP test
methods are superior; with very heavy involvement by
industry (ARA, 2014). While participants in this ‘Alliance for
Risk Assessment’ (ARA) project are aware that more sensitive
toxicity methods than the TG-GLP exist (ARA, 2013), most of
those involved appear to believe that improvements to the
existing methods – e.g. more data on mode of action or
exposures – will make risk assessment ‘fit for purpose’, the
Silver Book’s rubric for better risk assessment. Not only are
those improvements not needed to find toxic effects, but ARA
is promoting (ARA, 2013) methods such as the industry-
promoted TTC, which abandon any toxicity testing at all
(Pesticide Action Network Europe, 2012).
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in risk assessment. Independent academics could then be con-
tracted by governments to test the agent and analyse the inven-
tor's data – from its physio-chemical properties through to any
toxicity tests provided. When data is conﬂicting or lacking, there
should be a statutory precautionary bias when risk managers
decide the fate of an agent (along with further tests to decide the
question).
2.5.2. For previously-assesed agents: critical (systematic) review
A risk assessment's ﬁrst step, a literature review, is critical. Yet
these are pre-judged by the requirement for TG-GLP, usually via
Klimisch, to summarily dismiss other ﬁndings.
Mandates on industry to evaluate all literature on an agent are
starting to appear (e.g. in the EU's chemicals (REACh) and pesticide
laws), but our audits (ClientEarth, 2013; EEB, 2012, and one due
Sept. 2014 by Pesticide Action Network Europe) show these
mandate so far elicit reporting of no more than a quarter of
academia's published ﬁndings on an agent, with some companies
failing to report any published study. This attempt to improve the
critical ﬁrst step of risk assessment is failing. Critical reviews on an
agent are regularly published by academic investigators – e.g. on
bPA (Richter et al., 2007) – which would be a useful starting point
for a risk assessment, if an up to date one exists.
But to systematically determine the most reliable data, risk
assessors should adapt the ‘critical (systematic) review’ methods
of ‘evidence based medicine’ – the result of clinician's struggles to
interpret conﬂicting medical ﬁndings – chieﬂy the Cochrane
Collaboration (2014). A critical review aims ‘to minimise bias by
using explicit, systematic methods’ to review all the literature,
then critique it with objective, evidence-based criteria (Green et
al., 2008), creating the most reliable synthesis of current knowl-
edge (Woodruff and Sutton, 2010). Transparent presentation facil-
itates these difﬁcult evaluations, typically reaching consensus
(Evans et al., 2011).
Risk assessment agencies are moving towards more systematic
reviews, e.g. the Navigation Guide (Woodruff and Sutton, 2011)
and USNTP's Ofﬁce of Health Assessment and Translation, OHAT
(Bucher et al., 2011). Journal editors are beginning to screen animal
experiment manuscripts with the ARRIVE criteria to improve their
reproducibility (Tilson and Schroeder, 2013). Even traditional risk
assessment agencies and industry are moving towards systematic
review, e.g. the EU's Food and Feed Safety Assessments (EFSA,
2010); the Evidence-Based Toxicology Collaboration (Hartung,
2009).
Criteria on data quality are the key to successful critical/
systematic review. Some elements of TG-GLP tests, e.g. transpar-
ency of reporting, score high. Yet there is evidence that non TG-GLP
methods (including limiting ﬁnancial conﬂicts, as the Cochrane
guidelines have proposed) create more reproducible results
(Vesterinen et al., 2013). And a review of systematic review's
criteria ﬁnds that just one of 30 had been well validated (tested),
and most appear to promote insensitive toxicity test methods such
as the TG-GLP (Krauth et al., 2013). Another such comparison also
supports use of rigorous systematic review criteria, far beyond
what TG-GLP test methods offer (it tested 12 published bPA
chronic toxicity studies against a rigorous set of method criteria,
and even most of the reviewed authors agreed with their criti-
cisms) (Ågerstrand et al., 2014).
2.5.3. How to modify risk assessment: summary
Signiﬁcant data gaps are found in all risk assessment; they
should be ﬁlled using the above procedure to test new agents. Risk
assessment would then proceed as today: use the most potent of
the validated chronic NOAELs or LOAELs (or BMD) to base a safe
dose for all anticipated exposures.
Academic researchers could greatly contribute by using the
useful attributes of the TG-GLP methods; especially to homogenise
their toxicity test methods (to increase the comparability of
results) as far as possible, without sacriﬁcing their freedom to
hypothesise and test. Regulators making risk assessment and
management decisions should specify exactly their data needs,
in the following dialogue which we propose.
Industry would defend its interests in this system by providing
data showing that potent toxicity ﬁndings are false positives –
indications of test methods that overly sensitive and not speciﬁc
enough – although as with anyone's data, their ﬁndings would be
subject to independent conﬁrmation.
Industry has greatly increased its funding of academia in recent
decades (Zinner et al., 2009), raising doubts about the reliability of
academia's research. But academic researchers are historically
independent-minded, and academia's on-going publication of so
many low dose toxicity ﬁndings seems to show that we can rely on
them. Journals are greatly improving disclosure of ﬁnancially
conﬂicting interests (CoI), and everyone should speak up against
threats to academic objectivity. A role-playing study showed that
disclosure reduces both the number of CoI and how biased expert
advice is (Sah and Loewenstein, 2014).
Speciﬁc initiatives to make risk assessments more sensitive are
presented in Box 1.
2.6. Starting a dialogue
We do not expect the massive global system for assessing the
risks of chemical and other agents to change rapidly. Rather we
aim to expand a dialogue that recently began between represen-
tatives of the opposing toxicology paradigms we have described. It
erupted with an editorial from the editors-in-chief of 18 tradi-
tional toxicology journals (and 71 supporting researchers), saying
that the European Commission should make no changes to risk
assessment to assess endocrine disruptor risks, especially it should
keep assuming a safe dose exists (Dietrich et al., 2013), to avoid the
EU list for ban or restrictions. That elicited two ripostes from an
even greater number of editors and supporting scientists: in
Environmental Health (Bergman et al., 2013a) and in Endocrinol-
ogy (Gore et al., 2013). Importantly, the journalists at Environ-
mental Health Network revealed that of the 18 authors of Dietrich
2013, 17 failed to disclose ﬁnancial ties to industries whose agents
are subject to risk assessment, as did at least 40 of the 71
supporting scientists (EHN, 2013). But at least a dialogue on what
is reliable toxicity data has begun.
In addition, the NIEHS organised a 2012 global workshop in
Berlin (NIEHS, 2012) whose purpose was for regulators to talk with
the academic researchers who frequently ﬁnd non-monotonic and
low dose toxicities; aiming to incorporate such results into risk
assessment. But the challenge that non-monotonic results pose to
classic regulatory toxicology's core paradigm, ‘the dose makes the
poison,’ is hard to exaggerate. The NIEHS is encouraging continua-
tion of this dialogue. Helpfully the US National Academies of
Sciences has advised USEPA to re-consider the evidence of low
dose toxicity (namely non-monotonic), and to better adapt risk
assessment to account for non-monotonic risks (USNRC, 2014b).
3. Conclusion
The immediate task for risk assessment's stakeholders is to
develop the dialogue on the accuracy of TG-GLP versus academia's
test methods. The OECD's WNT committee a natural forum for further
dialogue. They originate and revise the TGs that are in global use, and
WNT members are representatives of the largest national chemical
agencies. They already discuss ad hoc test method issues with
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stakeholders, including some academic researchers (OECD, 2014b).
However, modern endocrinologists and other academics have the
knowledge the WNT needs to turn the TGs into more sensitive
toxicity methods – but their methods are not used. Anyone inter-
ested in this dialogue could contact us, inter alia.
People become upset (EC, 2013) when told they are perma-
nently contaminated (USCDC, 2013) with synthetic molecules they
did not evolve with. They pay taxes for academics to research
those risks with the best techniques, so their trust in regulators
erodes when they discover that this high quality data is of no
interest to the regulators, who instead use data from the party
whose interests conﬂict with knowledge. Toxicity testing also
comes at great cost to animal welfare – all the more reason that
its results be reliable, reﬂecting all methods validated in a
scientiﬁc ﬁeld (i.e., with accurate data, duplicate animal testing is
reduced). Many non-communicable chronic diseases are increas-
ing in incidence, chemicals being a leading suspect (Bergman et al.,
2013b). The primary prevention – not treatment or adaption – of
any such calamity cannot occur without more sensitive toxicity
test methods.
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